In addition to raised levels being seen with metformin treatment, NAD+ may be naturally regenerated by nicotinamide mononucleotide adenylyltransferase-3 (NMNAT3) as a protective mechanism against the mitochondrial dysfunction that precedes axon degeneration in glaucoma [182,183]. The gene discussed is NMNAT3; the disease is glaucoma.